Minerva Neurosciences, Inc. (NERV)
| Market Cap | 15.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.31M |
| Shares Out | 6.99M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,151 |
| Open | 2.140 |
| Previous Close | 2.130 |
| Day's Range | 2.140 - 2.228 |
| 52-Week Range | 2.060 - 13.490 |
| Beta | 0.09 |
| Analysts | Hold |
| Price Target | 5.00 (+131.48%) |
| Earnings Date | Nov 5, 2024 |
About NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. The company has a license a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NERV stock is "Hold" and the 12-month stock price forecast is $5.0.
News
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences: There's Probably Time For One More Rally
Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for ...
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispu...
Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Geoff Race - President Dr. Remy Luthringer - Executive Chairman and CEO Fred Ah...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 202...
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nerv...
Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Cal...
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET Company to Host Conference Call Today at 8:30 a.m. ET
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Management to Host Conference Call Management to Host Conference Call
Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick Ahlholm - CFO Confer...
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Company To Host Live Webcast Today at 8:30 a.m. ET Company To Host Live Webcast Today at 8:30 a.m. ET
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences to request meeting with FDA about schizophrenia drug
Minerva Neurosciences Inc. NERV, +7.61% said Monday that it received a refusal to file letter from the Food and Drug Administration for its application for roluperidone as a treatment for patients wit...
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner...
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
BURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervou...
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Third Quarter of 2022 Company Continues to Prepare for Potential Submission of an NDA for Roluperidone in the Th...
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarter of 2022 Company Expects to Submit an NDA for Roluperidone, Subject to FDA Guidance, in the Third Quarte...